お知らせ • Jan 08
BioCorRx Inc. Announces Board Changes, Effective January 1, 2026 BioCorRx Inc. announced that Louis Lucido has been appointed Chair of the Company’s Board of Directors, effective January 1, 2026. Mr. Lucido succeeded Kent Emry, who has served on BioCorRx’s Board of Directors since 2013 and will continue to serve as an independent director, ensuring continuity of leadership and governance. Mr. Lucido has been a member of the BioCorRx Board of Directors since 2019 and has played an instrumental role in the Company’s development and supporting operational leadership during a pivotal period for the Company as President since 2024. In addition, Mr. Lucido brings extensive board leadership experience, including service as Chair of the Board for other organizations, which positions him well to lead BioCorRx as it advances its strategic objectives. お知らせ • Apr 04
BioCorRx Inc. Announces Board Resignations On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “ Board”) of BioCorRx Inc. (the “ Company”), effective March 31, 2024 (the “ Granier Resignation”). Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “ Murthy Resignation”). The Granier Resignation and Murthy Resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals, a subsidiary of the Company. お知らせ • Feb 09
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, and Europe for the treatment of opioid use disorder. Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals Inc. She was previously Titan’s Chief Scientific Officer and has been with the company since 2007. During her tenure with Titan, Dr. DeVarney has been awarded and served as the Principal Investigator on multiple research grants funded by the National Institute on Drug Abuse (NIDA), and currently serves as an advisor on the National Advisory Committee on Drug Abuse (NACDA). Before joining Titan, she served as Senior Medical Director at Corcept Therapeutics Inc. and as Senior Medical Director for Neurosciences within World Wide Human Health at Merck & Co. Dr. DeVarney also held positions within the neurosciences research, development, and medical affairs organizations of SmithKline Beecham and GlaxoSmithKline. Throughout her academic and industry careers, Dr. DeVarney's research has focused primarily on substance use disorders, neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease, mood and anxiety disorders as well as metabolic disorders and obesity. Her research has been published in peer-reviewed medical journals such as The American Journal of Psychiatry, Drug and Alcohol Dependence, The Journal of the American Medical Association, and Addiction. She has also presented extensively at the American Psychiatric Association, the American College of Neuropsychopharmacology, the American Society of Addiction Medicine, and the International Society of Addiction Medicine. お知らせ • Jan 06
BioCorRx Inc. Announces President Changes On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. effective January 31, 2024. Mr. Granier will continue to serve as a member of the Company’s board of directors. Mr. Granier's resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals. On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024. Mr. Lucido will remain a member of the Board. Mr. Lucido, 75, was formerly the Senior Advisor and Chief Operating Officer of DoubleLine Group, LP. He was one of the five founding partners of DoubleLine in December of 2009. He was previously at TCW as a Group Managing Director. Prior to joining TCW in 2001, Mr. Lucido was the Chief Investment Officer for Delphi Financial Group (“DFG”) and on several subsidiary Boards. Before DFG, he was the Chief Operating Officer, MD, and Secretary for Hyperion Capital Management & was also a member of the Resolution Trust Advisory Committee. From 2013-2018, he served as a member of the Board of Directors of CASA of Los Angeles and Chair. Current member of the board for National CASA since 2018. Formerly served on the Boards of Junior Achievement, Southern California, 826LA, and the Lupus Research Alliance (formerly the Alliance for Lupus Research). Mr. Lucido received his MBA in Management and Finance from New York University and was a member of the Dean’s Advisory Board of the N.Y.U. Stern School of Business. Mr. Lucido has been a Director of BioCorRx Inc. since March 1, 2019. お知らせ • Jan 24
BioCorRx Inc. Appoints Harsha Murthy as A Member of the Board of Directors On January 20, 2023, BioCorRx Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”). The Company and Mr. Murthy entered in a Director Agreement, dated January 20, 2023 (the “Murthy Director Agreement”). Pursuant to the Murthy Director Agreement, Mr. Murthy shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position. Mr. Murthy will receive a quarterly cash stipend of $15,000. For so long as Mr. Murthy serves as the chair of either the Audit Committee of the Board, the Compensation Committee of the Board or the Nominating Committee of the Board, the amount of such quarterly cash stipend may be increased from time to time. Mr. Murthy will also be issued, upon the last day of each fiscal quarter, commencing in the quarter in which he enters into the Murthy Director Agreement, provided he is a member of the Board as of such date, the number of shares of the Company’s common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. お知らせ • Feb 24
BioCorRx Inc. Appoints Joseph J. Galligan as Member of the Board, Effective February 17, 2021 On February 16, 2021, the Board of Directors of BioCorRx Inc. appointed Mr. Joseph J. Galligan as a member of the Board, effective February 17, 2021. Mr. Galligan had served as senior advisor to the Company since April 2019. He was formerly an Executive Vice President and Portfolio Manager at DoubleLine Capital LP.